Original Article
Apolipoprotein E Genotype and the Risk of Recurrent Lobar Intracerebral Hemorrhage
N Engl J Med 2000; 342:240-245January 27, 2000
- Abstract
Background
Recurrent lobar intracerebral hemorrhage is the hallmark of cerebral amyloid angiopathy. The factors that predispose patients to early recurrence of lobar hemorrhage are unknown. One candidate is the apolipoprotein E gene, since both the ε2 and the ε4 alleles of apolipoprotein E appear to be associated with the severity of amyloid angiopathy.
Methods
We performed a prospective, longitudinal study of consecutive elderly patients who survived a lobar intracerebral hemorrhage. The patients were followed for recurrent hemorrhagic stroke by interviews at six-month intervals and reviews of medical records and computed tomographic scans.
Results
Nineteen of 71 enrolled patients had recurrent hemorrhages during a mean (±SD) follow-up period of 23.9±14.8 months, yielding a 2-year cumulative rate of recurrence of 21 percent. The apolipoprotein E genotype was significantly associated with the risk of recurrence. Carriers of the ε2 or ε4 allele had a two-year rate of recurrence of 28 percent, as compared with only 10 percent for patients with the common apolipoprotein E ε3/ε3 genotype (risk ratio, 3.8; 95 percent confidence interval, 1.2 to 11.6; P=0.01). Early recurrence occurred in eight patients, four of whom had the uncommon ε2/ε4 genotype. Also at increased risk for recurrence were patients with a history of hemorrhagic stroke before entry into the study (two-year recurrence, 61 percent; risk ratio, 6.4; 95 percent confidence interval, 2.2 to 18.5; P<0.001).
Conclusions
The apolipoprotein E genotype can identify patients with lobar intracerebral hemorrhage who are at highest risk for early recurrence. This finding makes possible both the provision of prognostic information to patients with lobar hemorrhage and a method of targeting and assessing potential strategies for prevention.
Media in This Article
Figure 1
Kaplan–Meier Estimates of the Rate of Recurrence of Lobar Hemorrhage over Time.Table 1
Clinical and Genetic Characteristics of the 71 Patients.Article Activity
- Article
Cerebral amyloid angiopathy, defined by the deposition of congophilic material in vessels of the cortex and leptomeninges, is a major cause of intracerebral hemorrhage in the elderly.1,2 Hemorrhages related to amyloid angiopathy generally occur in the cortical and corticosubcortical (lobar) brain regions where the vascular amyloid deposits are most frequent, and occur less commonly in the cerebellum.3 Most patients recover from an initial lobar hemorrhage.4,5 Recurrent lobar hemorrhages are relatively common, however, and may cause greater morbidity and mortality than first hemorrhages.6-8
Little is known about the factors that predict early recurrence in elderly patients with lobar hemorrhage. Such information would be useful both in determining the prognosis for individual patients and in furthering our understanding of underlying pathogenic processes, such as amyloid angiopathy.
In the current study we examined the apolipoprotein E genotype as a potential risk factor for recurrent lobar hemorrhage. Apolipoprotein E is present in three common allelic forms in humans, designated ε2, ε3 (the most common), and ε4. Previously implicated as a risk factor for dyslipidemia9 and Alzheimer's disease,10 the apolipoprotein E genotype also appears to have an important role in the pathogenesis of cerebral amyloid angiopathy. Clinical and pathological studies of amyloid angiopathy–related hemorrhage have suggested that both the ε4 and the ε2 alleles of apolipoprotein E are possible risk factors for the presence and early onset of the disease.11-14 The prospective data reported here indicate a strong association as well with the risk of a recurrence of hemorrhage.
Methods
Recruitment of Patients
We performed a prospective, longitudinal cohort study of survivors of acute lobar hemorrhage. Subjects were recruited from among consecutive patients at least 55 years old who presented with primary lobar hemorrhage to the Massachusetts General Hospital or the Spaulding Rehabilitation Hospital in Boston from July 1994 to June 1998. We identified potential subjects by screening lists of all admissions to the neurology, neurosurgery, and internal-medicine services. All patients underwent routine clinical evaluation, including history taking and physical examination, laboratory testing, stool guaiac examination, chest radiography, and computed tomography of the brain. Base-line evaluation also included conventional spin–echo magnetic resonance imaging (MRI) in 54 patients and gradient–echo MRI sequences (which are sensitive to small chronic hemorrhages15,16) in 50 of the 71 patients in the final cohort.
Potential subjects were assessed by a study neurologist to determine whether they met the study criteria. The exclusion criteria were any hemorrhagic focus outside the lobar brain regions (e.g., basal ganglia, thalamus, or brain stem), the presence of another definite cause of hemorrhage (trauma, excessive warfarin therapy [as indicated by an international normalized ratio above 3.0], vasculitis, cerebral tumor, coagulopathy, or vascular malformation17), or death before hospital discharge. There were 103 patients with lobar intracerebral hemorrhage without another definite cause among the 197 elderly patients with intracerebral hemorrhage who were screened during this period, and 78 of them survived to hospital discharge. Among these 78 eligible patients, 71 (91 percent) consented to be followed as part of the study, and 70 (90 percent) gave blood samples for the determination of apolipoprotein E genotype. Most members of the cohort were white; the only exceptions were one Asian, one Hispanic, and one black patient.
All information on patients (clinical, radiographic, and pathological) was reviewed and recorded at the time of recruitment by staff members who had no knowledge of the genotype. Clinical information collected by the investigators at the time of index presentation included age, race or ethnic group, sex, history of hypertension (defined by the use of an antihypertensive agent before admission or for at least one week after presentation11), dementia (defined as progressive decline in memory, language, or other cognitive function before the occurrence of hemorrhagic stroke11), diabetes mellitus (defined by the regular use of a hypoglycemic agent before or after admission), and previous hemorrhagic stroke (i.e., occurring before the index lobar hemorrhage; defined by the presence of clinical symptoms with acute hemorrhage documented by neuroimaging). In the final study cohort of 71 patients, 49 met the criteria for probable cerebral amyloid angiopathy–related hemorrhage11 on the basis of pathological demonstration of amyloid angiopathy (10 patients) or gradient–echo MRI evidence of two or more hemorrhagic lesions in the lobar regions (39 patients), and 22 were considered to have possible cerebral amyloid angiopathy11 on the basis of radiographic demonstration of a solitary lobar hemorrhage.
This study was performed with the approval of and in accordance with the guidelines of the institutional review boards of Massachusetts General Hospital and Spaulding Rehabilitation Hospital and with the informed consent of all subjects or family members.
Follow-up
The patients were interviewed by telephone every six months through June 1999. During the interview, the patient, the care giver (typically a spouse or other family member), or both were asked whether the patient had had any type of stroke or new neurologic symptoms (with detailed examples provided) or a decline in memory, language, or other cognitive function over the previous six months. The care givers of 60 of the 71 patients were interviewed, including all care givers of patients with a history of dementia or any suggestion of cognitive impairment at follow-up. All reports of recurrent hemorrhagic stroke (in 19 of the 71 patients) were confirmed by direct review of pertinent medical records, computed tomographic (CT) scans, and available pathological specimens by a study investigator. The patients also continued to receive routine medical care from their primary physicians (internists or neurologists) during the follow-up period. Medical records from these visits were available for review for 42 of the 52 patients for whom there was no report of recurrent hemorrhage. In each case the medical records confirmed the absence of new symptoms or signs of stroke.
Determination of Apolipoprotein E Genotype
DNA was prepared from blood samples, and the apolipoprotein E genotype was determined by the polymerase-chain-reaction–restriction-enzyme method as previously described.17 The genotype was determined and recorded without knowledge of the patient's clinical characteristics.
Statistical Analysis
We used the Kaplan–Meier product-limit method to estimate the cumulative proportion of patients with recurrent hemorrhage in the overall sample and in groups stratified according to demographic, clinical, or genetic variables. The survival time was calculated from the date of onset of the index hemorrhage until the date of a recurrence or until the last known date without recurrence on the basis of interviews with the patient or care giver. Data were censored at the time of death from causes other than documented recurrent hemorrhage (14 patients) or loss of contact with the study personnel (4 patients); there was no association between these reasons for censoring and apolipoprotein E genotype. Hypothesis testing was performed by the log-rank test; the effects of predictive variables are expressed as risk ratios and 95 percent confidence intervals, calculated by the Cox proportional-hazards method. Age at study entry was analyzed as both a continuous variable and a categorical variable according to the median age of the cohort (<75 vs. ≥75 years); age at the onset of a first clinical hemorrhage was handled similarly. Apolipoprotein E genotype was analyzed as a categorical variable according to the presence or absence of the ε2 and ε4 alleles. Multivariate analysis was performed with the Cox proportional-hazards model, with the use of variables associated (P<0.1) with the risk of recurrence in the univariate testing. Similar methods were used to estimate the proportion of patients who died or had evidence of cognitive decline.
All analyses were performed with Stata software (College Park, Tex.). All tests of significance were two-tailed.
Results
The study cohort, consisting of 71 elderly survivors of lobar hemorrhage, was followed prospectively for an average (±SD) of 23.9±14.8 months (range, 0.2 to 53.9) after the initial hemorrhage. The base-line characteristics of the cohort, including the proportion with a clinical history of hypertension, diabetes mellitus, or dementia before the index hemorrhage, are shown in Table 1Table 1
Clinical and Genetic Characteristics of the 71 Patients.. The frequencies of the ε2 and ε4 alleles of apolipoprotein E were higher than those in control elderly populations, as noted previously.10,13 Just over half of the total cohort (38 of 70 patients for whom the genotype was determined) carried one or both of these alleles. One cohort member died from recurrent hemorrhage before a blood sample could be obtained for genotyping.Nineteen members of the cohort had recurrent symptomatic hemorrhages during follow-up, yielding an estimated two-year cumulative incidence of 21 percent (Table 2Table 2
Predictors of Recurrence of Hemorrhage.), or an incidence of 14.3 per 100 person-years. Eighteen patients had recurrent lobar hemorrhages and one had a cerebellar hemorrhage. All recurrent hemorrhages were in a different site from that of the index hemorrhage. The in-hospital mortality rate associated with recurrent hemorrhage was 42 percent (8 of 19 patients). Pathological review of specimens obtained at the time of hematoma resection (in three patients, including one with cerebellar hemorrhage) or autopsy (one patient) demonstrated cerebral amyloid angiopathy in all instances.Several clinical variables were examined for their effect on the risk of recurrence of hemorrhage (Table 2). The time to recurrence did not vary significantly with age (either at study entry or at the first clinical hemorrhage), sex, or the presence or absence of hypertension, dementia, or diabetes mellitus (P>0.4 for all variables). The risk was elevated, however, in the 10 patients with a history of hemorrhagic stroke before they entered the study (Figure 1AFigure 1
Kaplan–Meier Estimates of the Rate of Recurrence of Lobar Hemorrhage over Time.).The apolipoprotein E genotype was also a predictor of the risk of recurrence (Figure 1B). Among the 18 patients whose genotypes were known who had a recurrent hemorrhage, 14 were carriers of the ε2 or ε4 allele; the two-year recurrence rate in this subgroup was 28 percent. In contrast, only four patients with the common ε3/ε3 genotype had a recurrent hemorrhage; the two-year recurrence rate in this subgroup was 10 percent (risk ratio for carriers of ε2 or ε4, 3.8; 95 percent confidence interval, 1.2 to 11.6). An increased risk of recurrence was conferred by either ε2 or ε4 (Table 2). The ε2/ε4 genotype was associated with the earliest recurrences: four of the eight patients who had recurrences within the first six months of follow-up had this uncommon genotype. There were no differences in time to a recurrence between patients who were heterozygous for ε2 or ε4 and the small group of patients who were homozygous for ε2 (one patient) or ε4 (four patients).
A Cox proportional-hazards model was fitted to assess the independent contributions of the various predictor variables (Table 3Table 3
Multivariate Model for Time to a Recurrence of Hemorrhage.). Analysis of apolipoprotein E genotype demonstrated that ε2 and ε4 each exerted independent effects on recurrence (model 1). Adding previous hemorrhagic stroke to the model (model 2) reduced the effect of the ε2 allele to borderline statistical significance (P=0.1).Discussion
The data demonstrate a clear relation between the ε2 and ε4 alleles of apolipoprotein E and the risk of recurrent lobar hemorrhage. This finding suggests that ε2 and ε4 alleles might identify the patients in whom cerebral amyloid angiopathy is sufficiently severe and widespread to cause early recurrence. Supporting this interpretation is the correspondence noted between these alleles and the severity of specific aspects of amyloid angiopathy. Apolipoprotein E ε4 is associated with increased vascular deposition of the β-amyloid peptide,12,17-20 an effect that is statistically independent of the allele's association with plaque amyloid.17 Apolipoprotein E ε2, conversely, appears to promote degenerative changes, such as cracking and fibrinoid necrosis, in the amyloid-laden vessel wall.14,21 Both effects are specific to the vasculopathy of cerebral amyloid angiopathy, since neither allele is associated with other types of intracranial hemorrhage, such as hypertensive hemorrhage.11,22
The lack of pathological confirmation of cerebral amyloid angiopathy in most of our cohort raises the alternative possibility that ε2 and ε4 distinguish patients who have amyloid angiopathy from those who do not. Although this explanation cannot be excluded, several considerations argue against it as the primary mechanism for the effect of apolipoprotein E. Even when the analysis was restricted to the subgroup of 49 patients who met the more stringent research criteria for “probable cerebral amyloid angiopathy–related hemorrhage,” carriers of the ε2 or ε4 allele had higher rates of recurrence than carriers of the ε3/ε3 genotype. It should also be noted that despite its association with ε2 and ε4, amyloid angiopathy–related hemorrhage is not at all uncommon in persons with the apolipoprotein E ε3/ε3 genotype.13,14 Indeed, the distribution of apolipoprotein E allele frequencies in pathologically documented cases of cerebral amyloid angiopathy2 is quite similar to that in our cohort (Table 1).
The apolipoprotein E genotype did not predict the risk of recurrence with certainty, a finding that suggests the existence of other risk factors. One such predictive factor was hemorrhagic stroke before the index lobar hemorrhage, which was more directly linked to recurrence, in statistical terms, than was the apolipoprotein E genotype (Table 3). We interpret these two types of risk factors somewhat differently, since previous hemorrhage, in contrast to a genetic factor, is unlikely to have a causal role in recurrence. Previous hemorrhage instead probably acts as a marker of other genetic or environmental risk factors for aggressive disease, both known risk factors (e.g., apolipoprotein E ε2, which is present at the markedly elevated allelic frequency of 40 percent among patients with previous hemorrhage) and those yet to be identified. The association between previous and recurrent hemorrhage also underscores the fact that recurrences do not occur at random, but are a characteristic of particularly aggressive diseases.
None of the other clinical risk factors we examined affected the risk of recurrence in this cohort. Hypertension, in particular, did not significantly affect the risk of recurrence, despite its important role as a risk factor for hemorrhage in the elderly23 and for the recurrence of hypertensive-type hemorrhage.6,24 Several considerations make this conclusion somewhat tentative. Since the presence of hypertension was determined on the basis of the history or during hospitalization rather than through systematic outpatient monitoring, it is possible that variations in blood pressure during follow-up may have had a minor effect on the risk of recurrence. Another possibility that was not examined is that uncontrolled hypertension (probably precluded in our cohort by the primary care received by all patients) might substantially affect the risk of recurrence. From a practical standpoint, attentive control of hypertension remains the prudent course in patients with suspected amyloid angiopathy.
The association between the ε2 and ε4 alleles of apolipoprotein E and the progression of cerebral amyloid angiopathy adds independent support to the evidence implicating these alleles as risk factors for this disease. The data are particularly intriguing for the small group of patients with the apolipoprotein E ε2/ε4 genotype, who appear to have the earliest onset of amyloid angiopathy–related hemorrhage14 as well as the highest risk of early recurrence. Observations in this subgroup suggest that enhancement of both β-amyloid deposition (by ε4) and vascular degeneration (by ε2) may lead to a particularly malignant course of disease. The association between apolipoprotein E and the course of cerebral amyloid angiopathy also offers interesting contrasts with Alzheimer's disease, which, once established, appears not to be accelerated by the presence of the apolipoprotein E ε4 allele.25-28 This distinction presumably arises from differences in the pathogenic pathways leading from amyloid deposition to tissue destruction in the two diseases.2
The results presented here pertain specifically to symptomatic hemorrhage that is sufficiently severe to bring the patient to medical attention and prompt the performance of CT. Future studies will determine whether similar risk factors govern the small, clinically asymptomatic hemorrhages that also characterize cerebral amyloid angiopathy.29 These silent hemorrhages may be approximately twice as frequent as symptomatic hemorrhages, according to recent observations drawn from serial gradient–echo MRI studies of a subgroup of asymptomatic patients in the current cohort.30
Recurrent hemorrhagic stroke appeared to be the principal contributor to poor outcome in our cohort of survivors of initial lobar hemorrhage. Among the 19 patients with recurrences, 8 did not survive to hospital discharge, another 4 died within six months of recurrence, and only 5 (26 percent) were able to return to even partially independent living. Members of the cohort who did not have recurrences, conversely, had a relatively good clinical course. The survival rate in this subgroup was 88 percent one year and 78 percent three years after entry into the cohort. Although cerebral amyloid angiopathy is also associated with an increased risk of Alzheimer's disease,1 as well as subcortical ischemic dementia,31,32 our patients did not have extraordinarily high rates of cognitive decline. Among 53 patients who did not have dementia before or immediately after the index hemorrhage, 89 percent remained free of dementia after one year of follow-up and 77 percent after three years. These figures are similar to those for dementia-free survival after ischemic stroke.33 Three of the eight new occurrences of dementia were related to recurrent hemorrhage. Taken together, these data indicate that prevention of recurrence would be an important step toward improving the outcome after lobar hemorrhage.
Our results raise the possibility that determination of the apolipoprotein E genotype might be clinically useful in assessing a patient's prognosis with respect to recurrent lobar hemorrhage. It should be emphasized, however, that the data refer expressly to recurrent rather than initial hemorrhage: the apolipoprotein E genotype is neither sensitive nor specific for the primary diagnosis of cerebral amyloid angiopathy. Another possible application of these data would be to identify the patients with the highest risk of recurrence for the purpose of testing potential protective agents in clinical trials.
Supported by grants from the National Institutes of Health (AG00725), the American Heart Association, and the Edward Mallinckrodt, Jr., Foundation.
We are indebted to Dr. G. William Rebeck and Dr. Merit Cudkowicz for their critical reading of the manuscript; to Dr. Yuchiao Chang for statistical review; and to Dr. Diane Karluk for assistance in reviewing pathological specimens.
Source Information
From the Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston.
Address reprint requests to Dr. Greenberg at Massachusetts General Hospital, Wang ACC 836, Boston, MA 02114, or at greenberg@helix.mgh.harvard.edu.
- References
References
1
Vinters HV . Cerebral amyloid angiopathy: a critical review. Stroke 1987;18:311-324
CrossRef | Web of Science | Medline2
Greenberg SM . Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology 1998;51:690-694
Web of Science | Medline3
Itoh Y ,Yamada M ,Hayakawa M ,Otomo E ,Miyatake T . Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J Neurol Sci 1993;116:135-141
CrossRef | Web of Science | Medline4
Kase CS ,Williams JP ,Wyatt DA ,Mohr JP . Lobar intracerebral hematomas: clinical and CT analysis of 22 cases. Neurology 1982;32:1146-1150
Web of Science | Medline5
Massaro AR ,Sacco RL ,Mohr JP , et al. Clinical discriminators of lobar and deep hemorrhages: the Stroke Data Bank. Neurology 1991;41:1881-1885
Web of Science | Medline6
Passero S ,Burgalassi L ,D'Andrea P ,Battistini N . Recurrence of bleeding in patients with primary intracerebral hemorrhage. Stroke 1995;26:1189-1192
CrossRef | Web of Science | Medline7
Counsell C ,Boonyakarnkul S ,Dennis M , et al. Primary intracerebral haemorrhage in the Oxfordshire Community Stroke Project. 2. Prognosis. Cerebrovasc Dis 1995;5:26-34
CrossRef | Web of Science8
Neau JP ,Ingrand P ,Couderq C , et al. Recurrent intracerebral hemorrhage. Neurology 1997;49:106-113
Web of Science | Medline9
Wilson PW ,Myers RH ,Larson MG ,Ordovas JM ,Wolf PA ,Schaefer EJ . Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA 1994;272:1666-1671
CrossRef | Web of Science | Medline10
Mayeux R ,Saunders AM ,Shea S , et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998;338:506-511[Erratum, N Engl J Med 1998;338:1325.]
Full Text | Web of Science | Medline11
Greenberg SM ,Briggs ME ,Hyman BT , et al. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996;27:1333-1337
CrossRef | Web of Science | Medline12
Premkumar DR ,Cohen DL ,Hedera P ,Friedland RP ,Kalaria RN . Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol 1996;148:2083-2095
Web of Science | Medline13
Nicoll JA ,Burnett C ,Love S , et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997;41:716-721
CrossRef | Web of Science | Medline14
Greenberg SM ,Vonsattel JP ,Segal AZ , et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998;50:961-965
Web of Science | Medline15
Greenberg SM ,Finklestein SP ,Schaefer PW . Petechial hemorrhages accompanying lobar hemorrhage: detection by gradient-echo MRI. Neurology 1996;46:1751-1754
Web of Science | Medline16
Offenbacher H ,Fazekas F ,Schmidt R ,Koch M ,Fazekas G ,Kapeller P . MR of cerebral abnormalities concomitant with primary intracerebral hematomas. AJNR Am J Neuroradiol 1996;17:573-578
Web of Science | Medline17
Greenberg SM ,Rebeck GW ,Vonsattel JPV ,Gomez-Isla T ,Hyman BT . Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995;38:254-259
CrossRef | Web of Science | Medline18
Schmechel DE ,Saunders AM ,Strittmatter WJ , et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:9649-9653
CrossRef | Web of Science | Medline19
Olichney JM ,Hansen LA ,Galasko D , et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996;47:190-196
Web of Science | Medline20
Alonzo NC ,Hyman BT ,Rebeck GW ,Greenberg SM . Progression of cerebral amyloid angiopathy: accumulation of amyloid-β40 in affected vessels. J Neuropathol Exp Neurol 1998;57:353-359
CrossRef | Web of Science | Medline21
McCarron MO ,Nicoll JA ,Stewart J , et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol 1999;58:711-718
CrossRef | Web of Science | Medline22
McCarron MO ,Nicoll JA . High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. Neurosci Lett 1998;247:45-48
CrossRef | Web of Science | Medline23
Broderick J ,Brott T ,Tomsick T ,Leach A . Lobar hemorrhage in the elderly: the undiminishing importance of hypertension. Stroke 1993;24:49-51
CrossRef | Web of Science | Medline24
Arakawa S ,Saku Y ,Ibayashi S ,Nagao T ,Fujishima M . Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke 1998;29:1806-1809
CrossRef | Web of Science | Medline25
Corder EH ,Saunders AM ,Strittmatter WJ , et al. Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 1995;45:1323-1328
Web of Science | Medline26
Gomez-Isla T ,West HL ,Rebeck GW , et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62-70
CrossRef | Web of Science | Medline27
Kurz A ,Egensperger R ,Haupt M , et al. Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996;47:440-443
Web of Science | Medline28
Stern Y ,Brandt J ,Albert M , et al. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997;41:615-620
CrossRef | Web of Science | Medline29
Gilles C ,Brucher JM ,Khoubesserian P ,Vanderhaeghen JJ . Cerebral amyloid angiopathy as a cause of multiple intracerebral hemorrhages. Neurology 1984;34:730-735
Web of Science | Medline30
Greenberg SM ,O'Donnell HC ,Schaefer PW ,Kraft E . MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology 1999;53:1135-1138
Web of Science | Medline31
Gray F ,Dubas F ,Roullet E ,Escourolle R . Leukoencephalopathy in diffuse hemorrhagic cerebral amyloid angiopathy. Ann Neurol 1985;18:54-59
CrossRef | Web of Science | Medline32
Greenberg SM ,Vonsattel JP ,Stakes JW ,Gruber M ,Finklestein SP . The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage. Neurology 1993;43:2073-2079
Web of Science | Medline33
Tatemichi TK ,Paik M ,Bagiella E , et al. Risk of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 1994;44:1885-1891
Web of Science | Medline
- Citing Articles (101)
Citing Articles
1
Usha K. Misra, Jayantee Kalita, Bindu I. Somarajan, Bishwanath Kumar, Moromi Das, Balraj Mittal. (2011) Do ACE (rs4646994) and αADDUCIN (rs4961) gene polymorphisms predict the recurrence of hypertensive intracerebral hemorrhage?. Neurological Sciences
CrossRef2
H. Bart Brouwers, Joshua N. Goldstein. (2011) Therapeutic Strategies in Acute Intracerebral Hemorrhage. Neurotherapeutics
CrossRef3
Anand Viswanathan, Steven M. Greenberg. (2011) Cerebral amyloid angiopathy in the elderly. Annals of Neurology 70:6, 871-880
CrossRef4
J. P. Cata, B. Abdelmalak, E. Farag. (2011) Neurological biomarkers in the perioperative period. British Journal of Anaesthesia
CrossRef5
Matthew A Kirkman, Stuart M Allan, Adrian R Parry-Jones. (2011) Experimental intracerebral hemorrhage: avoiding pitfalls in translational research. Journal of Cerebral Blood Flow & Metabolism 31:11, 2135-2151
CrossRef6
H. Matsukawa, M. Shinoda, M. Fujii, O. Takahashi, D. Yamamoto, A. Murakata, R. Ishikawa. (2011) Factors associated with lobar vs. non-lobar intracerebral hemorrhage. Acta Neurologica Scandinavicano-no
CrossRef7
Hidetoshi Matsukawa, Masaki Shinoda, Motoharu Fujii, Osamu Takahashi, Daisuke Yamamoto, Atsushi Murakata, Ryoichi Ishikawa. (2011) Impact of body mass index on the location of spontaneous intracerebral hemorrhage. World Neurosurgery
CrossRef8
Jonathan Elmer, Daniel J. Pallin, Shan Liu, Catherine Pearson, Yuchiao Chang, Carlos A. Camargo, Steven M. Greenberg, Jonathan Rosand, Joshua N. Goldstein. (2011) Prolonged Emergency Department Length of Stay is not Associated with Worse Outcomes in Patients with Intracerebral Hemorrhage. Neurocritical Care
CrossRef9
Andreas Charidimou, David J Werring. (2011) Cerebral microbleeds: detection, mechanisms and clinical challenges. Future Neurology 6:5, 587-611
CrossRef10
Yi Zhang, Xin Wang, Caleb Schultz, Giuseppe Lanzino, Alejandro A Rabinstein. (2011) Post-operative Outcome of Cerebral Amyloid Angiopathy-related Lobar Intracerebral Hemorrhage: Case Series and Systematic Review. Neurosurgery1
CrossRef11
Yi-Cheng Zhu, Hugues Chabriat, Ophélia Godin, Carole Dufouil, Jonathan Rosand, Steven M. Greenberg, Eric E. Smith, Christophe Tzourio, Anand Viswanathan. (2011) Distribution of white matter hyperintensity in cerebral hemorrhage and healthy aging. Journal of Neurology
CrossRef12
SHEHNAZ SULTANA, VENKATA K. KOLLA, YASOVANTHI JEEDIGUNTA, PRANAY K. PENAGALURU, SINDHU JOSHI, P. USHA RANI, P. P. REDDY. (2011) Tumour necrosis factor alpha and interleukin 10 gene polymorphisms and the risk of ischemic stroke in south Indian population. Journal of Genetics 90:2, 361-364
CrossRef13
P. Kirchhof, G. Y. H. Lip, I. C. Van Gelder, J. Bax, E. Hylek, S. Kaab, U. Schotten, K. Wegscheider, G. Boriani, A. Brandes, M. Ezekowitz, H. Diener, L. Haegeli, H. Heidbuchel, D. Lane, L. Mont, S. Willems, P. Dorian, M. Aunes-Jansson, C. Blomstrom-Lundqvist, M. Borentain, S. Breitenstein, M. Brueckmann, N. Cater, A. Clemens, D. Dobrev, S. Dubner, N. G. Edvardsson, L. Friberg, A. Goette, M. Gulizia, R. Hatala, J. Horwood, L. Szumowski, L. Kappenberger, J. Kautzner, A. Leute, T. Lobban, R. Meyer, J. Millerhagen, J. Morgan, F. Muenzel, M. Nabauer, C. Baertels, M. Oeff, D. Paar, J. Polifka, U. Ravens, L. Rosin, W. Stegink, G. Steinbeck, P. Vardas, A. Vincent, M. Walter, G. Breithardt, A. J. Camm. (2011) Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace
CrossRef14
Álvaro Cervera, Sergio Amaro, Ángel Chamorro. (2011) Oral anticoagulant-associated intracerebral hemorrhage. Journal of Neurology
CrossRef15
Navdeep Sangha, Nicole R. Gonzales. (2011) Treatment Targets in Intracerebral Hemorrhage. Neurotherapeutics 8:3, 374-387
CrossRef16
M. Rodríguez-Yáñez, M. Castellanos, M.M. Freijo, J.C. López Fernández, J. Martí-Fàbregas, F. Nombela, P. Simal, J. Castillo, E. Díez-Tejedor, B. Fuentes, M. Alonso de Leciñana, J. Álvarez-Sabin, J. Arenillas, S. Calleja, I. Casado, A. Dávalos, F. Díaz-Otero, J.A. Egido, J. Gállego, A. García Pastor, A. Gil-Núñez, F. Gilo, P. Irimia, A. Lago, J. Maestre, J. Masjuan, P. Martínez-Sánchez, E. Martínez-Vila, C. Molina, A. Morales, F. Purroy, M. Ribó, J. Roquer, F. Rubio, T. Segura, J. Serena, J. Tejada, J. Vivancos. (2011) Guías de actuación clínica en la hemorragia intracerebral. Neurología
CrossRef17
Sebastian Koch. (2011) Intracerebral hemorrhage: Preventing recurrence of ICH—should statins be avoided?. Nature Reviews Neurology 7:4, 193-194
CrossRef18
Aleksandra Maruszak, Cezary Żekanowski. (2011) Mitochondrial dysfunction and Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:2, 320-330
CrossRef19
Kohei Hasegawa, Megan L. Fix, Lauren Wendell, Kristin Schwab, Hakan Ay, Eric E. Smith, Steven M. Greenberg, Jonathan Rosand, Joshua N. Goldstein, David F.M. Brown. (2011) Ischemic-appearing electrocardiographic changes predict myocardial injury in patients with intracerebral hemorrhage. The American Journal of Emergency Medicine
CrossRef20
F. Block. (2011) Zerebrale Amyloidangiopathie. Der Nervenarzt 82:2, 202-206
CrossRef21
Kevin N Sheth, Aaron J Gilson, Yuchiao Chang, Mona A Kumar, Rosanna M Rahman, Natalia S Rost, Kristin Schwab, Lynelle Cortellini, Joshua N Goldstein, Eric E Smith, Steven M Greenberg, Jonathan Rosand. (2011) Packed Red Blood Cell Transfusion and Decreased Mortality in Intracerebral Hemorrhage. Neurosurgery1
CrossRef22
J. Attems, K. Jellinger, D. R. Thal, W. Van Nostrand. (2011) Review: Sporadic cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology 37:1, 75-93
CrossRef23
M. Àngels Font, Jerzy Krupinski, Adrià Arboix. (2011) Antithrombotic Medication for Cardioembolic Stroke Prevention. Stroke Research and Treatment 2011, 1-23
CrossRef24
P. Kirchhof, G. Y. H. Lip, I. C. Van Gelder, J. Bax, E. Hylek, S. Kaab, U. Schotten, K. Wegscheider, G. Boriani, M. Ezekowitz, H. Diener, H. Heidbuchel, D. Lane, L. Mont, S. Willems, P. Dorian, P. Vardas, G. Breithardt, A. J. Camm. (2011) Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Thrombosis and Haemostasis 106:6,
CrossRef25
Helen Kim, Ludmila Pawlikowska, William L. Young. 2011. Genetics and Vascular Biology of Brain Vascular Malformations. , 169-186.
CrossRef26
Carlos S. Kase, Steven M. Greenberg, J.P. Mohr, Louis R. Caplan. 2011. Intracerebral Hemorrhage. , 531-588.
CrossRef27
Masatoshi Takeda, Rocío Martínez, Takashi Kudo, Toshihisa Tanaka, Masayasu Okochi, Shinji Tagami, Takashi Morihara, Ryota Hashimoto, Ramón Cacabelos. (2010) Apolipoprotein E and central nervous system disorders: Reviews of clinical findings. Psychiatry and Clinical Neurosciences 64:6, 592-607
CrossRef28
Yu-Wei Chen, Ming-Jen Lee, Eric E. Smith. (2010) Reviews: Cerebral amyloid angiopathy in East and West. International Journal of Stroke 5:5, 403-411
CrossRef29
Vitaly Vasilevko, Giselle F. Passos, Daniel Quiring, Elizabeth Head, Richard C. Kim, Mark Fisher, David H. Cribbs. (2010) Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Annals of the New York Academy of Sciences 1207:1, 58-70
CrossRef30
Lea Tenenholz Grinberg, Dietmar Rudolf Thal. (2010) Vascular pathology in the aged human brain. Acta Neuropathologica 119:3, 277-290
CrossRef31
Bindu I Somarajan, J. Kalita, U.K. Misra, B. Mittal. (2010) A study of α1 antichymotrypsin gene polymorphism in Indian stroke patients. Journal of the Neurological Sciences 290:1-2, 57-59
CrossRef32
Kevin N. Sheth, Tracy A. Cushing, Lauren Wendell, Michael H. Lev, Javier M. Romero, Kristin Schwab, Eric E. Smith, Steven M. Greenberg, Jonathan Rosand, Joshua N. Goldstein. (2010) Comparison of Hematoma Shape and Volume Estimates in Warfarin Versus Non-Warfarin-Related Intracerebral Hemorrhage. Neurocritical Care 12:1, 30-34
CrossRef33
Romina M. Uranga, Jeffrey N. Keller. (2010) Diet and Age Interactions with Regards to Cholesterol Regulation and Brain Pathogenesis. Current Gerontology and Geriatrics Research 2010, 1-14
CrossRef34
Yi-Chun Chen, Guey-Jen Lee-Chen, Yih-Ru Wu, Fen-Ju Hu, Hsiu-Chuan Wu, Hung-Chou Kuo, Chun-Che Chu, Shan-Jin Ryu, Sien-Tsong Chen, Chiung-Mei Chen. (2009) Analyses of interaction effect between apolipoprotein E polymorphism and alcohol use as well as cholesterol concentrations on spontaneous deep intracerebral hemorrhage in the Taiwan population. Clinica Chimica Acta 408:1-2, 128-132
CrossRef35
Tamas Revesz, Janice L. Holton, Tammaryn Lashley, Gordon Plant, Blas Frangione, Agueda Rostagno, Jorge Ghiso. (2009) Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica 118:1, 115-130
CrossRef36
Margaret C. Fang. (2009) Antithrombotic therapy for the treatment of atrial fibrillation in the elderly. Journal of Interventional Cardiac Electrophysiology 25:1, 19-23
CrossRef37
Monisha A. Kumar, Natalia S. Rost, Ryan W. Snider, Rishi Chanderraj, Steven M. Greenberg, Eric E. Smith, Jonathan Rosand. (2009) Anemia and hematoma volume in acute intracerebral hemorrhage. Critical Care Medicine 37:4, 1442-1447
CrossRef38
Joshua N. Goldstein, Louis E. Fazen, Lauren Wendell, Yuchiao Chang, Natalia S. Rost, Ryan Snider, Kristin Schwab, Rishi Chanderraj, Christopher Kabrhel, Catherine Kinnecom, Emilie FitzMaurice, Eric E. Smith, Steven M. Greenberg, Jonathan Rosand. (2009) Risk of Thromboembolism Following Acute Intracerebral Hemorrhage. Neurocritical Care 10:1, 28-34
CrossRef39
P. Rønning, W. Sorteberg, P. Nakstad, D. Russell, E. Helseth. (2008) Aspects of intracerebral hematomas - an update. Acta Neurologica Scandinavica 118:6, 347-361
CrossRef40
R.N.K. Nandigam, A. Viswanathan, P. Delgado, M.E. Skehan, E.E. Smith, J. Rosand, S.M. Greenberg, B.C. Dickerson. (2008) MR Imaging Detection of Cerebral Microbleeds: Effect of Susceptibility-Weighted Imaging, Section Thickness, and Field Strength. American Journal of Neuroradiology 30:2, 338-343
CrossRef41
Fernando D. Testai, Venkatesh Aiyagari. (2008) Acute Hemorrhagic Stroke Pathophysiology and Medical Interventions: Blood Pressure Control, Management of Anticoagulant-Associated Brain Hemorrhage and General Management Principles. Neurologic Clinics 26:4, 963-985
CrossRef42
Jason K. Wasserman, Helen Yang, Lyanne C. Schlichter. (2008) Glial responses, neuron death and lesion resolution after intracerebral hemorrhage in young vs. aged rats. European Journal of Neuroscience 28:7, 1316-1328
CrossRef43
Patrick M. Sullivan, Brian E. Mace, Januario C. Estrada, Donald E. Schmechel, Mark J. Alberts. (2008) Human Apolipoprotein E4 Targeted Replacement Mice Show Increased Prevalence of Intracerebral Hemorrhage Associated with Vascular Amyloid Deposition. Journal of Stroke and Cerebrovascular Diseases 17:5, 303-311
CrossRef44
Hasan Kocaeli, Mario Zuccarello. (2008) Management of Spontaneous Intracerebral Hematomas. Neurosurgery Quarterly 18:3, 207-215
CrossRef45
Patrick C. Hsieh, Issam A. Awad, Christopher C. Getch, Bernard R. Bendok, Szymon S. Rosenblatt, H. Hunt Batjer. (2008) Current Updates in Perioperative Management of Intracerebral Hemorrhage. Neurosurgery Clinics of North America 19:3, 401-414
CrossRef46
D. M. Campbell, S. Bruins, H. Vogel, L. M. Shuer, C. A. C. Wijman. (2008) Intracerebral hemorrhage caused by cerebral amyloid angiopathy in a 53-year-old man. Journal of Neurology 255:4, 597-598
CrossRef47
J. Attems, F. Lauda, K. A. Jellinger. (2008) Unexpectedly low prevalence of intracerebral hemorrhages in sporadic cerebral amyloid angiopathy. Journal of Neurology 255:1, 70-76
CrossRef48
Katja E. Wartenberg, Stephan A. Mayer. (2007) Reducing the risk of ICH enlargement. Journal of the Neurological Sciences 261:1-2, 99-107
CrossRef49
Eric Jüttler, Thorsten Steiner. (2007) Treatment and prevention of spontaneous intracerebral hemorrhage: comparison of EUSI and AHA/ASA recommendations. Expert Review of Neurotherapeutics 7:10, 1401-1416
CrossRef50
Keith A. Johnson, Matt Gregas, John A. Becker, Catherine Kinnecom, David H. Salat, Erin K. Moran, Erin E. Smith, Jonathan Rosand, Dorene M. Rentz, William E. Klunk, Chester A. Mathis, Julie C. Price, Steven T. DeKosky, Alan J. Fischman, Steven M. Greenberg. (2007) Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Annals of Neurology 62:3, 229-234
CrossRef51
Margaret C. Fang, Alan S. Go, Yuchiao Chang, Elaine M. Hylek, Lori E. Henault, Nancy G. Jensvold, Daniel E. Singer. (2007) Death and Disability from Warfarin-Associated Intracranial and Extracranial Hemorrhages. The American Journal of Medicine 120:8, 700-705
CrossRef52
K. A. Jellinger, F. Lauda, J. Attems. (2007) Sporadic cerebral amyloid angiopathy is not a frequent cause of spontaneous brain hemorrhage. European Journal of Neurology 14:8, 923-928
CrossRef53
Joshua M. Levine, Ryan Snider, David Finkelstein, Mahmut E. Gurol, Rishi Chanderraj, Eric E. Smith, Steven M. Greenberg, Jonathan Rosand. (2007) Early edema in warfarin-related intracerebral hemorrhage. Neurocritical Care 7:1, 58-63
CrossRef54
Ralf W. Baumgartner, Adrian M. Siegel, Peter H. Hackett. (2007) Going High with Preexisting Neurological Conditions. High Altitude Medicine & Biology 8:2, 108-116
CrossRef55
Luís F. Maia, Ian R.A. Mackenzie, Howard H. Feldman. (2007) Clinical phenotypes of Cerebral Amyloid Angiopathy. Journal of the Neurological Sciences 257:1-2, 23-30
CrossRef56
M. Marietta, P. Pedrazzi, M. Girardis, G. Torelli. (2007) Intracerebral haemorrhage: an often neglected medical emergency. Internal and Emergency Medicine 2:1, 38-45
CrossRef57
Marco Fontanella, Innocenzo Rainero, Salvatore Gallone, Elisa Rubino, Chiara Rivoiro, Walter Valfrè, Diego Garbossa, Chiara Nurisso, Alessandro Ducati, Lorenzo Pinessi. (2007) Lack of association between the apolipoprotein E gene and aneurysmal subarachnoid hemorrhage in an Italian population. Journal of Neurosurgery 106:2, 245-249
CrossRef58
R. N. Kaveer Nandigam, Yu-Wei Chen, Mahmut E. Gurol, Jonathan Rosand, Steven M. Greenberg, Eric E. Smith. (2007) Validation of Intracranial Area as a Surrogate Measure of Intracranial Volume When Using Clinical MRI. Journal of Neuroimaging 17:1, 74-77
CrossRef59
Rosa Suñer Soler. (2007) La Prevención De La Enfermedad Vascular Cerebral Aguda. Revista Científica de la Sociedad Española de Enfermería Neurológica 2007:26, 38-44
CrossRef60
Patrick C. Hsieh, Issam A. Awad, Christopher C. Getch, Bernard R. Bendok, Szymon S. Rosenblatt, H. Hunt Batjer. (2006) Current Updates in Perioperative Management of Intracerebral Hemorrhage. Neurologic Clinics 24:4, 745-764
CrossRef61
Steven M. Greenberg, Jonathan Rosand, Alexander T. Schneider, L. Creed Pettigrew, Samuel E. Gandy, Barry Rovner, Brian-Fred Fitzsimmons, Eric E. Smith, M. Edip Gurol, Kristin Schwab, Julie Laurin, Denis Garceau. (2006) A Phase 2 Study of Tramiprosate for Cerebral Amyloid Angiopathy. Alzheimer Disease & Associated Disorders 20:4, 269-274
CrossRef62
Mark J Alberts. (2006) Do antiplatelet agents increase the risk of recurrent intracerebral hemorrhage?. Nature Clinical Practice Neurology 2:9, 480-481
CrossRef63
H. B. Huttner, E. Jüttler, A. Hug, M. Köhrmann, P. D. Schellinger, T. Steiner. (2006) Antikoagulanzienassoziierte Hirnblutungen. Der Nervenarzt 77:6, 671-681
CrossRef64
Ludmila Pawlikowska, K Y. Trudy Poon, Achal S. Achrol, Charles E. McCulloch, Connie Ha, Kristen Lum, Jonathan G. Zaroff, Nerissa U. Ko, S Claiborne Johnston, Stephen Sidney, Douglas A. Marchuk, Michael T. Lawton, Pui-Yan Kwok, William L. Young. (2006) Apolipoprotein E ϵ2 Is Associated with New Hemorrhage Risk in Brain Arteriovenous Malformations. Neurosurgery 58:5, 838-843
CrossRef65
Sandy X. Zhang-Nunes, Marion L. C. Maat-Schieman, Sjoerd G. Duinen, Raymund A. C. Roos, Matthew P. Frosch, Steven M. Greenberg. (2006) The Cerebral β-Amyloid Angiopathies: Hereditary and Sporadic. Brain Pathology 16:1, 30-39
CrossRef66
Luís F. Maia, Cristiana Vasconcelos, Susana Seixas, Rui Magalhães, Manuel Correia. (2006) Lobar Brain Hemorrhages and White Matter Changes: Clinical, Radiological and Laboratorial Profiles. Cerebrovascular Diseases 22:2-3, 155-161
CrossRef67
Leila A Shobab, Ging-Yuek R Hsiung, Howard H Feldman. (2005) Cholesterol in Alzheimer's disease. The Lancet Neurology 4:12, 841-852
CrossRef68
Neeraj Badjatia, Jonathan Rosand. (2005) Intracerebral Hemorrhage. The Neurologist 11:6, 311-324
CrossRef69
Chanhung Z Lee, William L Young. (2005) Management of brain arteriovenous malformations. Current Opinion in Anaesthesiology 18:5, 484-489
CrossRef70
Johannes Attems. (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathologica 110:4, 345-359
CrossRef71
Jonathan Rosand, Alona Muzikansky, Ashok Kumar, Jonathan J. Wisco, Eric E. Smith, Rebecca A. Betensky, Steven M. Greenberg. (2005) Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Annals of Neurology 58:3, 459-462
CrossRef72
Akifumi Izumihara, Michiyasu Suzuki, Tokuhiro Ishihara. (2005) Recurrence and extension of lobar hemorrhage related to cerebral amyloid angiopathy: multivariate analysis of clinical risk factors. Surgical Neurology 64:2, 160-164
CrossRef73
Rolf Kern, Stefan Kreisel, Saida Zoubaa, Kristina Szabo, Achim Gass, Michael Hennerici. (2005) Cognitive impairment, aphasia, and seizures in a 51-year-old man. The Lancet Neurology 4:7, 445-450
CrossRef74
W Andrew Kofke, Patrick Konitzer, Qing Cheng Meng, Jia Guo, Albert Cheung. (2004) The Effect of Apolipoprotein E Genotype on Neuron Specific Enolase and S-100?? Levels After Cardiac Surgery. Anesthesia & Analgesia1323-1325
CrossRef75
A. Hug, A. Aschoff, S. Schwab. (2004) Spontane intrazerebrale Blutungen. Der Nervenarzt 75:10, 953-961
CrossRef76
Mark O McCarron, James AR Nicoll. (2004) Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. The Lancet Neurology 3:8, 484-492
CrossRef77
M. D. Ezekowitz, R. H. Falk. (2004) The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation. Mayo Clinic Proceedings 79:7, 904-913
CrossRef78
Jessica A. Eng, Matthew P. Frosch, Kyungchan Choi, G. William Rebeck, Steven M. Greenberg. (2004) Clinical manifestations of cerebral amyloid angiopathy-related inflammation. Annals of Neurology 55:2, 250-256
CrossRef79
Carlos S. Kase, J.P. Mohr, Louis R. Caplan. 2004. Intracerebral Hemorrhage. , 327-376.
CrossRef80
Tanja Rundek, Ralph L. Sacco. 2004. Outcome following Stroke. , 35-57.
CrossRef81
Steven M. Greenberg. 2004. Cerebral Amyloid Angiopathy. , 693-705.
CrossRef82
Ralf Buhl, Harald Barth, Hubertus M. Mehdorn. (2003) Risk of recurrent intracerebral hemorrhages. Neurological Research 25:8, 853-856
CrossRef83
Matthew E. Fewel, B. Gregory Thompson, Julian T. Hoff. (2003) Spontaneous intracerebral hemorrhage: a review. Neurosurgical FOCUS 15:4, 1-16
CrossRef84
David Gaist, Nancy L Pedersen, Markku Koskenvuo, Søren Bak, Simona Giampaoli, Kaare Christensen, Jaakko Kaprio. (2003) Stroke Research in GenomEUtwin. Twin Research and Human Genetics 6:5, 442-447
CrossRef85
Eric E. Smith, Steven M. Greenberg. (2003) Clinical diagnosis of cerebral amyloid angiopathy: Validation of the Boston Criteria. Current Atherosclerosis Reports 5:4, 260-266
CrossRef86
K. Chalmers, G. K. Wilcock, S. Love. (2003) APOEe4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Abeta protein. Neuropathology and Applied Neurobiology 29:3, 231-238
CrossRef87
John T O'Brien, Timo Erkinjuntti, Barry Reisberg, Gustavo Roman, Tohru Sawada, Leonardo Pantoni, John V Bowler, Clive Ballard, Charles DeCarli, Philip B Gorelick, Kenneth Rockwood, Alistair Burns, Serge Gauthier, Steven T DeKosky. (2003) Vascular cognitive impairment. The Lancet Neurology 2:2, 89-98
CrossRef88
Kenneth Butcher, Tracey Baird, Mark Parsons, Stephen Davis. (2002) Medical Management of Intracerebral Hemorrhage. Neurosurgery Quarterly 12:4, 261-278
CrossRef89
D WOO, J BRODERICK. (2002) Spontaneous intracerebral hemorrhage: epidemiology and clinical presentation. Neurosurgery Clinics of North America 13:3, 265-279
CrossRef90
N AYGUN, T MASARYK. (2002) Diagnostic imaging for intracerebral hemorrhage. Neurosurgery Clinics of North America 13:3, 313-334
CrossRef91
Innocenzo Rainero, Luigi M.E Grimaldi, Giuliana Salani, Walter Valfrè, Lidia Savi, Chiara Rivoiro, Salvatore Gentile, Lorenzo Pinessi. (2002) Apolipoprotein E gene polymorphisms in patients with migraine. Neuroscience Letters 317:2, 111-113
CrossRef92
Imran Liaquat, Laurence T. Dunn, James A. R. Nicoll, Graham M. Teasdale, John D. Norrie. (2002) Effect of apolipoprotein E genotype on hematoma volume after trauma. Journal of Neurosurgery 96:1, 90-96
CrossRef93
Robert J. van Oostenbrugge, Jaap Troost. (2001) Aspects of stroke management including subarachnoid haemorrhage. Current Opinion in Anaesthesiology 14:5, 469-474
CrossRef94
M. J. MacLeod, R. P. De Lange, G. Breen, D. Meiklejohn, H. Lemmon, D. St Clair. (2001) Lack of association between apolipoprotein E genoype and ischaemic stroke in a Scottish population. European Journal of Clinical Investigation 31:7, 570-573
CrossRef95
Thomas J. Grabowski, Hyun Soon Cho, Jean Paul G. Vonsattel, G. William Rebeck, Steven M. Greenberg. (2001) Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Annals of Neurology 49:6, 697-705
CrossRef96
Qureshi, Adnan I., Tuhrim, Stanley, Broderick, Joseph P., Batjer, H. Hunt, Hondo, Hideki, Hanley, Daniel F., . (2001) Spontaneous Intracerebral Hemorrhage. New England Journal of Medicine 344:19, 1450-1460
Full Text97
Il Suh, Sun Ha Jee, Hyeon Chang Kim, Chung Mo Nam, Il Soon Kim, Lawrence J Appel. (2001) Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. The Lancet 357:9260, 922-925
CrossRef98
Richard Christie, Masaru Yamada, Michael Moskowitz, Bradley Hyman. (2001) Structural and Functional Disruption of Vascular Smooth Muscle Cells in a Transgenic Mouse Model of Amyloid Angiopathy. The American Journal of Pathology 158:3, 1065-1071
CrossRef99
Daniel L. Labovitz, Ralph L. Sacco. (2001) Intracerebral hemorrhage: update. Current Opinion in Neurology 14:1, 103-108
CrossRef100
Philippa J. Talmud, Dawn M. Waterworth. (2000) Genetics and molecular biology. Current Opinion in Lipidology 11:5, 555-557
CrossRef101
Sacco, Ralph L., . (2000) Lobar Intracerebral Hemorrhage. New England Journal of Medicine 342:4, 276-279
Full Text
